文献速递艾滋病与性传播感染细菌感染、耐药与抗菌药物

HIV病毒学抑制者换用BIC/FTC/TAF与继续DTG/3TC的炎症代谢结局相当

Comparable Inflammatory and Metabolic Outcomes After Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Continuing Dolutegravir/Lamivudine in Virologically Suppressed Adults With HIV (INSTINCT/GESIDA10918 Study).
PubMed 文献 · Clin Infect Dis · 2026-01-01

INSTINCT/GESIDA10918为IV期多中心开放标签随机试验,纳入141例稳定服用DTG/3TC且持续病毒学抑制的HIV-1成人,1:1随机继续原方案或换用BIC/FTC/TAF并随访96周。两组炎症生物标志物、CD4⁺与CD4/CD8比值、体重、血脂、血糖及eGFR均无显著差异,病毒学抑制率均>95%,不良事件轻微且均衡。

要点

  • 病毒学抑制者继续DTG/3TC或换用BIC/FTC/TAF,96周炎症与代谢结局相当。
  • 两组CD4⁺计数与CD4/CD8比值稳定且可比,病毒学抑制率均>95%。
  • 体重变化轻微且相似,≥5%体重增重比例无差异,血脂、血糖、eGFR无相关差异。

核心结论

  • 在病毒学抑制的HIV-1成人中,继续DTG/3TC与换用BIC/FTC/TAF在96周时系统炎症、代谢结局及免疫学标志物方面表现等效。

研究设计与样本

  • INSTINCT为IV期、多中心、开放标签、随机试验,纳入141例稳定服用DTG/3TC且持续病毒学抑制的HIV-1成人,按1:1随机分组并随访96周。
  • 于基线、第48周和第96周检测血浆生物标志物(sCD14、IL-6、sCD163、hsCRP、D-二聚体、犬尿氨酸/色氨酸比值),采用线性混合效应模型分析纵向变化。

主要发现

  • 96周内两组炎症生物标志物无显著组间差异。
  • CD4⁺T细胞计数与CD4/CD8比值保持稳定且两组可比。
  • 体重变化轻微且相似,≥5%体重增重比例无差异。
  • 血脂、血糖或eGFR未见相关差异,病毒学抑制在>95%的受试者中维持。
  • 不良事件轻微且两组间均衡。

临床怎么用

  • 对已稳定使用DTG/3TC且病毒学抑制者,换用BIC/FTC/TAF在炎症与代谢方面不优于继续原方案,可依据耐受性、合并用药与患者偏好个体化选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Dual antiretroviral therapy (ART) with dolutegravir/lamivudine (DTG/3TC) is widely used in virologically suppressed individuals. However, data remain limited on potential differential effects of ART regimens on mid-term systemic inflammation and metabolic health. We evaluated whether switching from DTG/3TC to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) modifies systemic inflammation or metabolic parameters. METHODS: INSTINCT was a phase IV, multicenter, open-label, randomized trial enrolling adults with HIV-1 on stable DTG/3TC and sustained viral suppression. Participants were randomized (1:1) to continue DTG/3TC or switch to BIC/FTC/TAF and followed for 96 weeks. Plasma biomarkers (sCD14, IL-6, sCD163, hsCRP, D-dimer, and kynurenine/tryptophan ratio) were measured at baseline, week 48, and week 96. Secondary outcomes included CD4⁺ and CD4/CD8 ratio, virological suppression, weight, lipid profile, and renal function. Longitudinal changes were analyzed using linear mixed-effects models. RESULTS: A total of 141 participants were randomized. Over 96 weeks, no significant between-group differences were observed in inflammatory biomarkers. CD4⁺ T-cell counts and CD4/CD8 ratio remained stable and comparable across arms. Weight changes were modest and similar; the proportion with ≥5% weight gain did not differ. No relevant differences were found in lipids, glucose, or eGFR. Virological suppression was maintained in >95% of participants. Adverse events were mild and balanced between groups. CONCLUSIONS: In virologically suppressed individuals, maintaining DTG/3TC or switching to BIC/FTC/TAF demonstrated equivalent profiles with respect to systemic inflammation, metabolic outcomes, and immunologic markers over 96 weeks.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Serrano-Villar S, Martín-Pedraza L, Tiraboschi J, et al. Comparable Inflammatory and Metabolic Outcomes After Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Continuing Dolutegravir/Lamivudine in Virologically Suppressed Adults With HIV (INSTINCT/GESIDA10918 Study). Clin Infect Dis. 2026. PMID: 41070447. doi:10.1093/cid/ciaf565

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。